| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Insider buying and selling activity across 114 companies in the Pharmaceuticals industry. Part of the Health Care sector.
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Nov 17, 2016 | CPIX Cumberland Pharmaceuticals Inc | Bonner Michael | Chief Financial Officer | Buy | 900 | $5.50 | $4,950.00 | +8.2% | |
| Nov 16, 2016 | ALKS Alkermes Plc. | Landine Michael J | SVP, Corp Dev., Alkermes, Inc. | Sell | 10,000 | $58.59 | $585,900.80 | -3.1% | |
| Nov 15, 2016 | ALKS Alkermes Plc. | Pops Richard F57 | Director And CEO, Alkermes Plc | Sell | 30,000 | $58.82 | $1,764,524.92 | -2.4% | |
| Nov 15, 2016 | PCRX Pacira Biosciences, Inc. | Stack David M67 | CEO And Chairman | Sell | 15,000 | $37.28 | $559,140.00 | -10.4% | |
| Nov 15, 2016 | PCRX Pacira Biosciences, Inc. | Scibetta James S | President | Sell | 20,000 | $36.50 | $730,000.00 | -42.5% | |
| Nov 15, 2016 | CPIX Cumberland Pharmaceuticals Inc | Lawrence Thomas R | Director | Sell | 18,600 | $5.07 | $94,302.00 | -41.0% | |
| Nov 15, 2016 | AMPH Amphastar Pharmaceuticals, Inc. | Lee Howard | Director | Sell | 37,994 | $20.65 | $784,680.46 | -14.2% | |
| Nov 11, 2016 | IRWD Ironwood Pharmaceuticals Inc | Gilbert Halley E | Chief Legal Officer | Sell | 14,000 | $16.75 | $234,500.00 | -100% | |
| Nov 11, 2016 | AMPH Amphastar Pharmaceuticals, Inc. | Prins Richard K61 | Director | Sell | 8,000 | $20.06 | $160,500.80 | -25.8% | |
| Nov 11, 2016 | EGRX Eagle Pharmaceuticals, Inc. | Proquest Investments Iv, L.P. | 10% Owner | Sell | 34,486 | $85.15 | $2,936,604.80 | -0.2% | |
| Nov 11, 2016 | LFCR Lifecore Biomedical, Inc. \de\ | Skinner Gregory S | VP Finance And Admin &CFO | Sell | 50,000 | $13.99 | $699,495.73 | -10.2% | |
| Nov 11, 2016 | RMTI Rockwell Medical, Inc. | Holt Kenneth L | Director | Sell | 19,725 | $5.16 | $101,687.25 | -6.4% | |
| Nov 10, 2016 | ALKS Alkermes Plc. | Breyer Robert A | Director | Sell | 20,000 | $60.00 | $1,200,000.00 | -56.9% | |
| Nov 10, 2016 | PAHC Phibro Animal Health Corp | Miller Larry Lee | Chief Operating Officer | Sell | 5,646 | $30.35 | $171,356.10 | -100% | |
| Nov 10, 2016 | MRK Merck & Co., Inc. | Frazier Kenneth C | Chairman, President &CEO | Sell | 140,000 | $65.03 | $9,104,486.32 | -12.1% | |
| Nov 9, 2016 | AMRN Amarin Corp Plc\uk | Kennedy Joseph T | General Counsel | Sell | 122,358 | $3.04 | $372,041.73 | -43.0% | |
| Nov 9, 2016 | ALKS Alkermes Plc. | Landine Michael J | SVP, Corp Dev., Alkermes, Inc. | Sell | 10,000 | $56.22 | $562,183.19 | -2.0% | |
| Nov 9, 2016 | EGRX Eagle Pharmaceuticals, Inc. | Proquest Investments Iv, L.P. | 10% Owner | Sell | 153,830 | $79.29 | $12,197,276.85 | -0.5% | |
| Nov 9, 2016 | ANIK Anika Therapeutics, Inc. | Bower Joseph I | Director | Sell | 540 | $43.39 | $23,432.40 | -0.7% | |
| Nov 8, 2016 | ALKS Alkermes Plc. | Pops Richard F57 | Director And CEO, Alkermes Plc | Sell | 30,000 | $53.28 | $1,598,462.48 | -2.4% | |
| Nov 7, 2016 | MRK Merck & Co., Inc. | Gerberding Julie L. | EVP Strat Comm, Gl Pub Policy | Sell | 85,523 | $60.02 | $5,133,329.92 | -68.6% | |
| Nov 4, 2016 | EGRX Eagle Pharmaceuticals, Inc. | Proquest Investments Iv, L.P. | 10% Owner | Sell | 245,770 | $71.02 | $17,455,384.89 | -1.9% | |
| Nov 2, 2016 | AYTU Aytu Biopharma, Inc | Disbrow Jarrett | Chief Operating Officer | Buy | 166,666 | $1.50 | $249,999.00 | +67.5% | |
| Nov 2, 2016 | MRK Merck & Co., Inc. | Wendell Peter C | Director | Sell | 5,000 | $59.50 | $297,500.00 | -83.3% | |
| Nov 2, 2016 | AYTU Aytu Biopharma, Inc | Gould Gregory A | Chief Financial Officer | Buy | 66,666 | $1.50 | $99,999.00 | +32.2% |
The blue line has two modes, toggled with the Relative and Absolute buttons:
Relative (default) shows cumulative industry performance with both the overall market and parent sector movements removed. When the line rises above 100, the industry is outperforming its sector; below 100 means underperforming. This is calculated using factor returns via weighted least squares (WLS) regression, isolating pure industry-specific behavior.
Absolute shows the total cumulative return of the industry including market and sector movement. This reflects what an investor actually experienced — an industry can show strong absolute gains even while underperforming its sector in relative terms.
Both views start at an index of 100. Other return drivers such as momentum, value, or size are deliberately retained in both modes, since these are part of what makes an industry behave the way it does and may reflect the conditions insiders are responding to.